Is PMVP or IFRX more profitable?

InflaRx's return on equity of -53.56% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% InflaRx N/A -53.56% -43.02%

Is FULC or PMVP more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -25.38% -24.15% PMV Pharmaceuticals N/A -78.11% -70.13%

Which has higher valuation & earnings, IMRX or PMVP?

Immuneering is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A

Is IMRX or PMVP more profitable?

Immuneering's return on equity of -27.15% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% PMV Pharmaceuticals N/A -78.11% -70.13%

PMV Pharmaceuticals (PMVP) Competitors

$1.50 +0.04 (+2.74%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.50 +0.00 (+0.07%)

As of 09/18/2026 07:56 PM Eastern

Compare

PMVP vs. IFRX, FATE, UPB, FULC, and IMRX

Should you buy PMV Pharmaceuticals stock or one of its competitors? PMV Pharmaceuticals's main competitors and comparable companies include InflaRx (IFRX), Fate Therapeutics (FATE), Upstream Bio (UPB), Fulcrum Therapeutics (FULC), and Immuneering (IMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PMV Pharmaceuticals compare to InflaRx?

PMV Pharmaceuticals (NASDAQ:PMVP) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

In the previous week, InflaRx had 6 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 6 mentions for InflaRx and 0 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.00 beat InflaRx's score of 0.39 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
PMV Pharmaceuticals	Positive
InflaRx	Neutral

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PMV Pharmaceuticals has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market.

InflaRx's return on equity of -53.56% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
InflaRx	N/A	-53.56%	-43.02%

InflaRx has higher revenue and earnings than PMV Pharmaceuticals. InflaRx is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
InflaRx	$30K	10,291.34	-$51.63M	-$0.58	N/A

PMV Pharmaceuticals currently has a consensus price target of $4.33, suggesting a potential upside of 188.89%. InflaRx has a consensus price target of $7.43, suggesting a potential upside of 254.59%. Given InflaRx's higher possible upside, analysts plainly believe InflaRx is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

InflaRx beats PMV Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Fate Therapeutics had 5 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 5 mentions for Fate Therapeutics and 0 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.00 beat Fate Therapeutics' score of 0.66 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Fate Therapeutics	Positive
PMV Pharmaceuticals	Positive

PMV Pharmaceuticals has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

PMV Pharmaceuticals has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	45.59	-$136.32M	-$1.05	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

Fate Therapeutics presently has a consensus target price of $5.90, suggesting a potential upside of 133.20%. PMV Pharmaceuticals has a consensus target price of $4.33, suggesting a potential upside of 188.89%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fate Therapeutics has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Summary

Fate Therapeutics and PMV Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Upstream Bio?

PMV Pharmaceuticals (NASDAQ:PMVP) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Upstream Bio had 3 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Upstream Bio and 0 mentions for PMV Pharmaceuticals. Upstream Bio's average media sentiment score of 1.57 beat PMV Pharmaceuticals' score of 1.00 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
PMV Pharmaceuticals	Positive
Upstream Bio	Very Positive

PMV Pharmaceuticals currently has a consensus price target of $4.33, indicating a potential upside of 188.89%. Upstream Bio has a consensus price target of $29.67, indicating a potential upside of 455.56%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

PMV Pharmaceuticals has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PMV Pharmaceuticals has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

PMV Pharmaceuticals has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
Upstream Bio	$2.85M	102.62	-$143.44M	-$2.90	N/A

Summary

PMV Pharmaceuticals and Upstream Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

In the previous week, Fulcrum Therapeutics had 3 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 0 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.00 beat Fulcrum Therapeutics' score of 0.32 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulcrum Therapeutics	Neutral
PMV Pharmaceuticals	Positive

Fulcrum Therapeutics has higher revenue and earnings than PMV Pharmaceuticals. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.59	-$74.88M	-$1.21	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

Fulcrum Therapeutics' return on equity of -25.38% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Fulcrum Therapeutics has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Fulcrum Therapeutics currently has a consensus target price of $8.20, suggesting a potential upside of 118.09%. PMV Pharmaceuticals has a consensus target price of $4.33, suggesting a potential upside of 188.89%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

PMV Pharmaceuticals beats Fulcrum Therapeutics on 8 of the 15 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Immuneering?

Immuneering (NASDAQ:IMRX) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Immuneering had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 1 mentions for Immuneering and 0 mentions for PMV Pharmaceuticals. Immuneering's average media sentiment score of 1.34 beat PMV Pharmaceuticals' score of 1.00 indicating that Immuneering is being referred to more favorably in the media.

Company	Overall Sentiment
Immuneering	Positive
PMV Pharmaceuticals	Positive

Immuneering currently has a consensus price target of $17.50, suggesting a potential upside of 290.63%. PMV Pharmaceuticals has a consensus price target of $4.33, suggesting a potential upside of 188.89%. Given Immuneering's stronger consensus rating and higher probable upside, equities analysts clearly believe Immuneering is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Immuneering's return on equity of -27.15% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

Immuneering has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Immuneering is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 14.9% of Immuneering shares are owned by company insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Immuneering beats PMV Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get PMV Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMVP vs. The Competition

Export

Metric	PMV Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$80.19M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-1.06	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.76	15.45	10.46	6.33
Net Income	-$77.74M	-$22.86M	$3.49B	$358.33M
7 Day Performance	7.14%	-1.21%	0.59%	1.12%
1 Month Performance	15.38%	-3.29%	-1.74%	-2.39%
1 Year Performance	14.50%	37.74%	18.13%	5.35%

PMV Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMVP PMV Pharmaceuticals	3.5375 of 5 stars	$1.50 +2.7%	$4.33 +188.9%	+14.5%	$80.19M	N/A	N/A	54	Positive News
IFRX InflaRx	2.0751 of 5 stars	$2.06 +1.0%	$7.43 +260.6%	+56.3%	$300.63M	$30K	N/A	65
FATE Fate Therapeutics	2.581 of 5 stars	$2.52 +3.3%	$5.90 +134.1%	+162.9%	$292.36M	$6.65M	N/A	161	High Trading Volume
UPB Upstream Bio	3.0583 of 5 stars	$5.31 -0.4%	$29.67 +458.7%	-67.4%	$291.93M	$2.85M	N/A	75	News Coverage Positive News
FULC Fulcrum Therapeutics	2.2581 of 5 stars	$3.77 -0.5%	$8.20 +117.5%	-49.1%	$289.17M	$80M	N/A	55

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMVP) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. IFRX, FATE, UPB, FULC, and IMRX

How does PMV Pharmaceuticals compare to InflaRx?

Summary

How does PMV Pharmaceuticals compare to Fate Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Upstream Bio?

Summary

How does PMV Pharmaceuticals compare to Fulcrum Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. IFRX, FATE, UPB, FULC, and IMRX

How does PMV Pharmaceuticals compare to InflaRx?

Does the media refer more to PMVP or IFRX?

Do insiders & institutionals hold more shares of PMVP or IFRX?

Which has more risk and volatility, PMVP or IFRX?

Is PMVP or IFRX more profitable?

Which has preferable earnings and valuation, PMVP or IFRX?

Do analysts prefer PMVP or IFRX?

Summary

How does PMV Pharmaceuticals compare to Fate Therapeutics?

Does the media prefer FATE or PMVP?

Is FATE or PMVP more profitable?

Which has higher valuation & earnings, FATE or PMVP?

Do analysts rate FATE or PMVP?

Do institutionals and insiders hold more shares of FATE or PMVP?

Which has more risk and volatility, FATE or PMVP?

Summary

How does PMV Pharmaceuticals compare to Upstream Bio?

Does the media favor PMVP or UPB?

Do analysts prefer PMVP or UPB?

Is PMVP or UPB more profitable?

Do institutionals & insiders have more ownership in PMVP or UPB?

Which has more risk and volatility, PMVP or UPB?

Which has better valuation and earnings, PMVP or UPB?

Summary

How does PMV Pharmaceuticals compare to Fulcrum Therapeutics?

Does the media refer more to FULC or PMVP?

Which has better valuation & earnings, FULC or PMVP?

Is FULC or PMVP more profitable?

Do insiders & institutionals have more ownership in FULC or PMVP?

Which has more risk & volatility, FULC or PMVP?

Do analysts recommend FULC or PMVP?

Summary

How does PMV Pharmaceuticals compare to Immuneering?

Does the media refer more to IMRX or PMVP?

Do analysts prefer IMRX or PMVP?

Is IMRX or PMVP more profitable?

Which has more volatility & risk, IMRX or PMVP?

Which has higher valuation & earnings, IMRX or PMVP?

Do institutionals & insiders have more ownership in IMRX or PMVP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools